USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ENDOPROTECH, INC.
Address:
1044 E CHESTNUT ST
LOUISVILLE, KY 40204-1019
Phone:
N/A
URL:
N/A
EIN:
270087238
DUNS:
144667602
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $277,707.00 1
STTR Phase I $122,978.00 1
STTR Phase II $963,666.00 1

Award List:

New anti-complement therapy to reduce reperfusion injury

Award Year / Program / Phase:
2005 / STTR / Phase I
Award Amount:
$122,978.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF LOUISVILLE
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The purpose of this proposal is to provide proof-of-concept that a novel therapy that prevents complement activation could be effective in reducing ischemia reperfusion injury (IRI) in transplanted organs. Complement activation after IRI in transplanted organs… More

New anti-complement therapy to reduce reperfusion injury: Phase II

Award Year / Program / Phase:
2008 / STTR / Phase II
Award Amount:
$963,666.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Tissue and organ transplantation procedures save and/or improve the lives of hundred of thousands of patients annually in the US. The goal of this research is to develop a local anti-complement therapy for donor organ e x vivo application that will reduce… More

Device for Delivery of Rolipram to Liver for Treatment of Alcoholic Liver Disease

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$277,707.00
Agency:
HHS
Principal Investigator:
Philip Bauer – 502-569-1020
Abstract:
DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) remains a leading cause of death from liver disease in the U.S., and there is still no FDA-approved therapy. Abnormal cytokine metabolism is a major feature of ALD. Elevated serum concentrations of tumor necrosis factor (TNF-) and… More